Resources for Food and Drug Administration (FDA)

Cardiome's CBO discusses changes at FDA

www.fiercebiotech.com

During a conference call with investors yesterday, Cardiome's President and Chief Business Officer, Doug Janzen, had some interesting thoughts on the slow approval process at the FDA:

"The FDA has actually come out and said it will be missing (PDUFA) dates... I think everyone is in a brand new environment... actually, some of the old-timers in the industry are talking about we're back in the old environment where the FDA just doesn't deal with timelines. They're missing PDUFA dates, they're missing type-C meetings, they're missing meetings to discuss protocol..."

Janzen's comments stem from the approval delay of Cardiome's intravenous drug vernakalant for atrial fibrillation. Despite being approved by an expert committee, the company has been awaiting FDA approval since the drug January 19th PDUFA date. His observations highlight the ongoing problems at the FDA. The agency is struggling to meet PDUFA dates, ensure food and drug safety, and maintain enough staff to deal with it's ever-growing list of responsibilities.

View the Resource

Share or bookmarklet this web page at: